春节长假画上句号，全国各地迎来复工潮。然而，不少人发现自己出现了身心疲惫、注意力难以集中， 甚至伴有焦虑或失落感等症状。这种被称为"节后综合征"的现象，本质上是身心平衡被假期模式打破 后，需要重新适应工作节奏的信号。京东互联网医院内科全职医生曹静指出，这本质上是身心平衡被假 期模式打破后，需要重新适应工作节奏的信号，无需过度紧张，但需要科学调整。 身体调整是复工"满血回归"的第一步。假期期间不少人作息紊乱，复工后切忌"报复性熬夜"，可以每天 比前一天提前15分钟至30分钟入睡，建立睡前"断电仪式"——远离手机和电脑，听轻音乐或温水泡脚， 连续3天至5天即可基本恢复正常作息。同时，无论多困都应坚持在固定时间起床，拉开窗帘接触自然 光，帮助重置生物钟。 饮食方面，假期往往高油高盐高糖，复工后应增加深色蔬菜和富含维生素C的水果摄入，保证优质蛋白 质，用温水、淡茶替代含糖饮料和过量咖啡，尤其是早餐一定要吃，为大脑提供"启动能量"。运动上不 必急于进行高强度锻炼，从快走、慢跑、瑜伽等"微运动"开始，每天20分钟至30分钟，让身体微微出汗 即可，运动能有效提升内啡肽水平，改善情绪和精力。 心理调适同样关键。首先要接纳"不 ...

春节长假画上句号，全国各地迎来复工潮。然而，不少人发现自己出现了身心疲惫、注意力难以集中、 甚至伴有焦虑或失落感等症状。这种被称为"节后综合征"的现象，本质上是身心平衡被假期模式打破 后，需要重新适应工作节奏的信号。京东互联网医院内科全职医生曹静指出，这本质上是身心平衡被假 期模式打破后，需要重新适应工作节奏的信号，无需过度紧张，但需要科学调整。 身体调整是复工"满血回归"的第一步。假期期间不少人作息紊乱，复工后切忌"报复性熬夜"，可以每天 比前一天提前15至30分钟入睡，建立睡前"断电仪式"——远离手机和电脑，听轻音乐或温水泡脚，连续 3至5天即可基本恢复正常作息。同时，无论多困都应坚持在固定时间起床，拉开窗帘接触自然光，帮助 重置生物钟。 饮食方面，假期往往高油高盐高糖，复工后应增加深色蔬菜和富含维生素C的水果摄入，保证优质蛋白 质，用温水、淡茶替代含糖饮料和过量咖啡，尤其是早餐一定要吃，为大脑提供"启动能量"。运动上不 必急于高强度锻炼，从快走、慢跑、瑜伽等"微运动"开始，每天20至30分钟，让身体微微出汗即可，运 动能有效提升内啡肽水平，改善情绪和精力。 心理调适同样关键。首先要接纳"不想上班"的念头 ...

近日，印度部分地区报告的尼帕病毒病例引发国际关注。我国国家疾控局发布研判指出，经综合评估， 此次疫情对我国造成的影响相对较小。目前，我国尚未发现尼帕病毒病病例，但也存在一定境外输入风 险，公众需提高防范意识，采取科学防护措施。 京东互联网医院 C7关注 ♀ 北京 ▼ ▽国家卫健委认证机构 · 1亿用户选择 > C 热伤风 搜索 #流感门诊 | #9.9特惠义诊 | #三甲肿瘤专家 领取京豆 > 免费 极速问诊 Al医生 24小时病情咨询 精选三甲/京东自营 不限次免费问答 30秒极速接诊 Al咨询 真人问诊 找医生 北京协和医院等多位医生已入驻 > 按科室/疾病找 专家在线 III在线 公立医院专家列表 · 三甲名医坐诊 · 权威 放心问 按医院找 99%用户好评 各科室全国重点医院 9秒接诊 专家加号 约线下就诊 | 极速视频 面对面视频 特色专科 全部特色专科 > 5 B 9 中医院 皮肤医院 心理中心 男科中心 问中医治根本 抑郁/焦虑等 秋冬护肤无忧 私密问诊 我的 皮肤医院 AI 医生大为 消息 首页 目前，京东互联网医院可提供24小时在线问诊服务，全国三甲医院医生在线接诊，平均响应时间约30 秒。 ...

Core Insights - The health consumption sector is undergoing significant generational changes, with a rapid increase in immediate, personalized, and scenario-based health demands, transforming instant retail into a new infrastructure for the pharmaceutical and health industry [1] - The instant retail market is projected to exceed 2 trillion yuan by 2030, with the O2O pharmaceutical sector expected to be a major growth driver [1] Group 1: Business Growth and Strategies - JD's "Buy Medicine in Seconds" service has seen over 100% year-on-year growth in partnered stores and a 200% increase in order volume, with a network covering 490 cities [1] - The service's full-chain solution, including platform policies, traffic support, and growth strategies, has become a key engine for driving business growth for partner merchants [2] - During the 618 shopping festival, order volume for "Buy Medicine in Seconds" surged over 400% year-on-year, with new user numbers increasing by over 600% [2] Group 2: Merchant Support and Incentives - A merchant evaluation system has been introduced to help stores quickly identify operational weaknesses, with over 100 merchants participating in the incentive program in 2025 [3] - The platform provides various support measures for new merchants, including dedicated service guidance, advertising subsidies, and traffic support [3] Group 3: Brand Value and Market Positioning - JD's service is helping pharmaceutical companies transition from merely selling products to delivering health value, supported by a nationwide supply network and rapid delivery capabilities [4] - The platform's insights into consumer behavior and category trends assist pharmaceutical companies in optimizing product strategies [4] Group 4: Marketing and Consumer Engagement - JD has launched targeted marketing campaigns, such as the "Warm Winter Delivery" initiative, which significantly increased GMV and new customer acquisition [5] - The marketing efforts focus on addressing user pain points and enhancing brand trust through meaningful engagement [5] Group 5: Future Developments and Innovations - The pharmaceutical O2O market is entering a critical phase of "value co-creation," with JD planning to leverage its digital capabilities to empower partners further [6][7] - The "京医千询" medical model and AI-driven tools are set to enhance intelligent product selection and precise marketing for merchants [7] - Future policies will include reduced shipping costs and incentives for high-growth merchants, aiming to lower operational costs and enhance growth certainty [7]

Group 1 - The core viewpoint is that AI in healthcare is integrated into national strategic planning, leading to an accelerated phase of industry development through a comprehensive policy framework [1][6] Group 2 - Infrastructure support focuses on standardization to enhance data interoperability and smart hospital construction, laying the groundwork for AI applications in healthcare [2] - Regulatory governance has established a tiered framework to balance innovation and safety, providing clear guidelines for AI medical software classification and lifecycle regulation [3] - Payment mechanism reforms are crucial for the commercialization of AI healthcare products, with policies supporting AI-assisted diagnosis and innovative payment models [4] Group 3 - Application scenarios are being expanded, with the government identifying key areas for AI in healthcare, creating a positive cycle of policy guidance and innovation [5] - The integration of AI with pharmaceutical manufacturing and healthcare services is encouraged, fostering a diversified innovation ecosystem [6] Group 4 - Shanghai is leading the way in medical AI development with the first provincial-level plan, aiming to create a nationally replicable model for AI in healthcare [7] - The plan emphasizes enhancing innovation sources, building support platforms, and creating comprehensive application scenarios in clinical and public health [8][9][10] Group 5 - Companies are focusing on three critical elements: application scenarios, data, and computing power, which are essential for breakthroughs in the AI healthcare industry [11][12] - There is a pressing need for high-value application scenarios, as many AI technologies face challenges in adapting to clinical and industry needs [13][14] - Data sharing and quality are significant concerns, with companies advocating for unified data-sharing mechanisms to overcome barriers [16][17] - The demand for computing power is high, and companies are calling for centralized computing resources to reduce costs and improve efficiency [17] Group 6 - The trend of companies expanding internationally is becoming essential, with different paths for AI in drug development and medical devices [18] - AI in drug development is characterized by a dual approach of licensing out and independent international expansion, focusing on regions with established clinical trial systems [19][20] - AI in medical devices is pursuing multiple strategies to adapt to global market needs, including remote surgery and tailored solutions [20] Group 7 - A comparison of capabilities between Chinese and American companies in various AI healthcare fields shows differences in market maturity and regulatory environments [30] Group 8 - Specialized medical models are gaining traction, with hospitals leading the deployment of AI models tailored to specific diseases [34] - Evidence-based medicine is being utilized to address challenges in AI reliability and accuracy [37][38] Group 9 - The emergence of embodied intelligence is expected to bridge the gap between digital healthcare and physical health services, focusing on autonomous medical interventions and human-robot collaboration [45][49][51] Group 10 - AI technology is fundamentally reshaping the healthcare industry by enhancing operational efficiency and expanding access to quality medical resources [54] - The shift from hospital-centered systems to personal health information systems marks a significant transformation in healthcare delivery, emphasizing proactive health management [56][60]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The report emphasizes the clear trend of AI in the healthcare industry, driven by policy implementation and technological breakthroughs. Key policies include the State Council's directive on AI in healthcare, aiming for widespread application of AI in diagnosis, health management, and insurance services by 2030 [10][11] - The report identifies the G-end and B-end commercial models as relatively mature, while the C-end applications, particularly the Ant Financial's "Afu" app, are still developing. The app has over 30 million monthly active users, with a significant portion from lower-tier cities [11][12] - The report highlights the importance of monitoring upcoming catalysts in 2026, including AI partnerships and new model releases from major tech companies [10][11] Summary by Sections 1. AI Empowering Healthcare Industry Development - AI is set to enhance the healthcare industry chain, with policies accelerating the integration of AI in medical services, public health, and health industry development [13] - The report outlines various AI application scenarios in healthcare, including intelligent diagnosis and drug development [13][15] 2. AI Healthcare Stock Price Movements - Stock price drivers in AI healthcare include policy changes, technological advancements, and performance realization [4] - The report notes significant technological breakthroughs and product applications in the past three years, with a focus on upcoming key events in 2026 [4][11] 3. G-end and B-end Commercialization - The G-end and B-end business models are highlighted as more established, with G-end focusing on government and healthcare needs, while B-end targets hospitals and pharmaceutical companies [11] - The C-end model is primarily based on drug sales through AI health applications, with the Ant Financial's "Afu" app leading in user engagement [11][12] 4. Key Investment Targets - The report suggests focusing on companies such as MedLinker, JD Health, Alibaba Health, iFlytek Medical Technology, Ping An Good Doctor, and Ruanda Medical for potential investment opportunities [12][11]

Core Viewpoint - JD.com has achieved a record revenue of 1.15 trillion yuan, surpassing Alibaba by nearly 180 billion yuan and Huawei by approximately 300 billion yuan, establishing itself as China's largest private enterprise and the only private company with over a trillion yuan in revenue [1][3][5]. Group 1: Revenue and Workforce - JD.com reported a total revenue of 1.1588 trillion yuan, significantly exceeding Alibaba's 984.7 billion yuan and Huawei's 860 billion yuan, marking it as the largest private enterprise in China [3][5]. - The company employs 670,000 staff members, contributing to its substantial revenue generation [1]. Group 2: Employee Welfare and Business Strategy - JD.com has invested heavily in employee welfare, with over 116.1 billion yuan spent on labor costs last year, and offers a housing loan program for employees, providing up to 1 million yuan [1][9]. - The company has implemented a strategy of full social insurance coverage for all delivery personnel, enhancing employee satisfaction and loyalty [7][9]. Group 3: JD Health and Growth Potential - JD Health has shown remarkable growth, with total revenue projected to increase by 8.6% to 58.2 billion yuan in 2024, becoming a significant profit driver for the group [10]. - The introduction of innovative health products, such as "Xiaoniu Acid," has led to substantial revenue growth, with JD Health's net profit reaching 2.44 billion yuan, accounting for nearly a quarter of the group's total profit [17]. Group 4: Market Position and Competitive Advantage - JD.com has established a robust logistics network with 3,600 smart warehouses and a storage area equivalent to 4,500 football fields, enabling rapid order fulfillment [7]. - The company has successfully penetrated the high-net-worth consumer market, with 77% of households earning over 500,000 yuan annually making purchases on JD.com [12]. Group 5: Contribution to National Economy - Private enterprises in China, including JD.com, have collectively generated 41 trillion yuan in revenue, significantly contributing to the national economy and employment [21]. - The government is supporting private enterprises through tax reductions and encouraging technological advancements, allowing companies like JD.com to thrive [23].

Group 1 - The core viewpoint of the articles highlights the launch of an AI-driven clinical nutrition management solution by JD Health in collaboration with Wenzhou Medical University First Affiliated Hospital and the National Health Commission's Clinical Nutrition and Intervention Key Laboratory, aimed at improving medical quality and patient outcomes under the "Healthy China 2030" strategy [2] - The solution encompasses seven key stages of patient care, including screening, assessment, diagnosis, treatment, control, management, and education, establishing an integrated management system of "system—formulation—quality control" [2] - The technical core of the solution is the "Clinical Nutrition Large Model," developed collaboratively, which utilizes JD Health's proprietary medical model "JD Medical Qianxun" and has been trained on over one million nutrition-related literature and tens of thousands of real clinical cases [2] Group 2 - JD Health's "JD Zhuoyi 2.0" model, an integral part of its full-scenario large model product, can be embedded into existing hospital systems, facilitating a closed-loop from in-hospital diagnosis to out-of-hospital continuous management [3] - The collaboration with Wenzhou Medical University First Affiliated Hospital has already served over 4.7 million patients through the "Clinical Nutrition + Special Medical Food" service network, indicating the model's scalability for nationwide promotion [3] - JD Health's CEO, Cao Dong, emphasized the company's commitment to opening its leading "super pharmaceutical supply chain" capabilities and medical AI products to a broader range of partners, aiming to build a safe, reliable, and efficient "new infrastructure for medical digitization" [3]

Core Viewpoint - JD Group is undergoing a strategic transformation from a traditional e-commerce platform to a comprehensive solution provider for the silver economy, addressing the pressing societal question of elder care as the population aged 60 and above exceeds 310 million in China, accounting for 22% of the total population [2] Group 1: Infrastructure Development - The core issue in elder care services is the shortage of professional talent, with a significant gap between 44 million disabled elderly individuals and only about 300,000 certified caregivers. JD has chosen a heavy asset investment approach [4] - By the end of 2023, JD's home service training base in Wanzhou, Chongqing, will be operational, covering 20,000 square meters and providing systematic training for caregivers to offer standardized care for disabled elderly individuals [4] - JD plans to invest 1 billion yuan over the next three years to build a training system, with over 150 standardized training bases and a pioneering "three-level training network" model to enhance professional skills and dignity among workers [4] Group 2: Digital Health Services - JD Health is evolving from product sales to health management, utilizing its self-developed medical model "JD Medical Inquiry" to launch AI doctors and pharmacists, addressing nearly 30% of health consultations during nighttime, which meets the immediate needs of the elderly [5] - In the smart hardware sector, sales of age-friendly medical devices such as dynamic blood glucose monitors and hearing aids have increased by over 100%. JD is creating a health management loop that transitions elderly care from "availability of medication" to "scientific management" [5] Group 3: Community Service Network - The key to implementing the silver economy lies in community integration. JD's partnership with local streets through JD Fresh Kitchen provides elder meal assistance services [6] - In the field of home adaptation for the elderly, JD has co-developed group standards and launched strategic new products, planning to procure over 1 million age-friendly products [6] Group 4: Challenges and Collaborative Solutions - Despite the promising outlook, the elder care industry faces deep-rooted challenges such as limited payment capacity and difficulties in service standardization. JD's strategy may involve ecological collaboration, transforming elder care services into high-frequency service entry points [8] - This approach aims to create a service loop of health management, home adaptation, and daily care, which could reinforce its retail and logistics core business, distinguishing it from traditional elder care providers [8] Group 5: Broader Implications - JD's engagement in the silver economy transcends commercial interests, reflecting a new phase where Chinese tech companies integrate deeply with industrial and societal issues. This model of heavy asset investment in infrastructure, standardization to enhance service quality, and ecological collaboration to create value offers new insights for the industry [9] - When corporate strategies resonate with national development issues, commercial value aligns with social value, highlighting the responsibility of leading enterprises in the face of demographic changes [9]

Group 1 - JD Health held the 2026 Medical Device Development Strategy Conference, focusing on supply, AI, and medical services as core drivers for growth [1] - The company signed agreements with the top 100 global brands to launch new products in 2026, committing over 100 million in marketing resources [1] - JD Health aims to enhance its medical device sector by leveraging its supply chain, AI technology, and internet medical services to create a comprehensive ecosystem [1] Group 2 - In 2025, JD Health plans to deepen global brand collaborations and introduce overseas supplies through large-scale procurement [2] - The company will focus on high-potential areas such as chronic disease management and home healthcare, aiming to transition from single product sales to comprehensive health management solutions [2] - JD Health is committed to driving innovation and sustainable development in the medical device industry by enhancing product offerings and AI technology [2]